Physician profile
Gladys E Palomeno
NPI 1164522116
$10,382.28
in general payments reported to CMS, 2019-2025
43 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $1,638 · 2021: $1,923 · 2022: $1,037 · 2023: $1,152 · 2024: $1,330 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,547.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,350.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Mannkind Corporation | $1,325.60 | 2019-2025 | Afrezza |
| Amgen INC. | $1,187.47 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $795.60 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $724.87 | 2019-2025 | |
| Lilly USA, LLC | $716.78 | 2020-2025 | Zepbound, Mounjaro, Trulicity |
| Dexcom, INC. | $522.66 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $416.20 | 2019-2025 | Korlym |
| Insulet Corporation | $316.28 | 2019-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $299.22 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $242.50 | 2019-2025 | Licart, Tirosint, Flector |
| Endo Pharmaceuticals INC. | $237.07 | 2020-2022 | |
| Radius Health, INC. | $218.79 | 2023-2025 | Tymlos |
| Horizon Therapeutics Plc | $216.80 | 2019-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $130.86 | 2020-2023 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.13 | 2022-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $123.97 | 2021-2023 | Evkeeza, Praluent |
| Amarin Pharma, INC. | $120.16 | 2019-2021 | |
| Valeritas, INC. | $109.08 | 2019 | |
| Ascendis Pharma Endocrinology INC | $100.69 | 2024-2025 | Yorvipath |
| Currax Pharmaceuticals LLC | $99.29 | 2020-2025 | Contrave |
| Kyowa Kirin, INC. | $96.89 | 2023-2025 | Crysvita |
| Medtronic, INC. | $87.49 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Astrazeneca Pharmaceuticals LP | $79.32 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $75.00 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $74.12 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $64.17 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $61.40 | 2019 | |
| Alvogen INC | $60.49 | 2025 | Teriparatide |
| Vivus LLC | $57.19 | 2021-2025 | Qsymia |
| Sequel Med Tech, LLC | $54.26 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $46.40 | 2022-2025 | Gvoke Hypopen |
| Acella Pharmaceuticals, LLC | $29.11 | 2025 | NP Thyroid 60 |
| Beta Bionics, INC. | $27.81 | 2023 | Ilet Bionic Pancreas |
| Merck Sharp & Dohme LLC | $24.81 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.84 | 2020 | |
| Vertical Pharmaceuticals, LLC | $23.49 | 2019 | |
| Ascend Therapeutics US, LLC | $22.22 | 2021 | |
| Recordati_rare_diseases_inc. | $22.04 | 2025 | Isturisa |
| Kowa Pharmaceuticals America, INC. | $20.71 | 2023 | Livalo, Seglentis |
| Vertiflex, INC. | $18.49 | 2019 | |
| Avion Pharmaceuticals | $16.26 | 2022 | |
| Cequr Corporation | $14.99 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gladys Palomeno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.